Cases of substantial personal losses, sometimes exceeding six figures, illustrate the human impact
Whether you're a healthcare professional, a patient dealing with obesity, or simply someone interested in weight loss, this article is for you
Earlier this month, Danish pharma giant Novo Nordisk released the first GLP-1 pill for obesity, and rival Eli Lilly is planning to release its own version later this year
Semaglutide, on the other hand was designed to address the challenges of liraglutide, particularly its once daily dosing
Its GLP-1 and GIP receptor activation primarily modulates innate immune responses, specifically macrophage polarization and cytokine production